Literature DB >> 1287915

Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom.

J A Scott1, R N Davidson, A H Moody, H R Grant, D Felmingham, G M Scott, P Olliaro, A D Bryceson.   

Abstract

We report 11 patients with leishmaniasis from different endemic areas, treated in the UK with intravenous aminosidine alone or in combination with other drugs. Clinical and parasitological cures were achieved in all 7 patients from the Mediterranean zone who had visceral disease, with one relapse. Two of 4 patients with cutaneous or mucosal disease were cured; the other 2, from Iraq and Iran, did not respond. Toxic effects were high-tone deafness in 2 patients, one of whom had pre-existing renal impairment, and transient, mild elevation of serum creatinine in 3. Aminosidine is an effective, tolerable and relatively non-toxic alternative to existing antileishmanial drugs for the treatment of visceral leishmaniasis. Further studies will be needed to assess its place in cutaneous and mucosal disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287915     DOI: 10.1016/0035-9203(92)90151-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

1.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

Review 2.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.

Authors:  T P Kanyok; A D Killian; K A Rodvold; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Amine-Linked Flavonoids as Agents Against Cutaneous Leishmaniasis.

Authors:  Chin-Fung Chan; Zhen Liu; Iris L K Wong; Xianliang Zhao; Zaofeng Yang; Jiale Zheng; Marianne M Lee; Michael K Chan; Tak Hang Chan; Larry M C Chow
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

5.  Ubiquitination-mediated interaction among domains is responsible for inhibition of RNA endonuclease activity of mRNA cycling sequence binding protein from L. donovani (LdCSBP).

Authors:  Kasturi Guha; Dipankar Bhandari; Titash Sen; Partha Saha
Journal:  Parasitol Res       Date:  2014-06-08       Impact factor: 2.289

6.  Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.

Authors:  P R Donald; F A Sirgel; T P Kanyok; L H Danziger; A Venter; F J Botha; D P Parkin; H I Seifart; B W Van De Wal; J S Maritz; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

8.  Ribosomes of Leishmania are a target for the aminoglycosides.

Authors:  M Maarouf; F Lawrence; S L Croft; M Robert-Gero
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

9.  Leishmania infantum AS A CAUSATIVE AGENT OF CUTANEOUS LEISHMANIASIS IN THE STATE OF MATO GROSSO DO SUL, BRAZIL.

Authors:  Ludiele Souza Castro; Adriana de Oliveira França; Eduardo de Castro Ferreira; Günther Hans Filho; Minoru German Higa Júnior; Célia Maria Ferreira Gontijo; Agnes Antônia Sampaio Pereira; Maria Elizabeth Moraes C Dorval
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-03-22       Impact factor: 1.846

Review 10.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Authors:  Lucio H Freitas-Junior; Eric Chatelain; Helena Andrade Kim; Jair L Siqueira-Neto
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-28       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.